Solvay Preparing Announcement On Cilansetron NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Solvay receives a response letter from FDA one week ahead of the user fee deadline for the irritable bowel syndrome product. Solvay is currently assessing the letter's contents, the company says.